The total value of the global cell dissociation market was USD 381 million in 2022, and it will rise at a growth rate of above 17.10% shortly, reaching USD 1,347 million by 2030, according to P&S Intelligence.
 |
| To learn more about this report: https://bit.ly/3HRnMKs |
This growth can be ascribed to the rising consciousness of stem cell research, the growing improvements in technology, and the rising requirement for modified drug and monoclonal antibodies.
Furthermore, the growing occurrence of communicable and chronic illnesses, the growing count of medicinal and biotechnology businesses, and rising government investments in the growth of new medications are boosting the need for cell dissociation.
The increasing occurrence of chronic diseases primarily cancer, continued expansion in the biotechnology and pharmaceutical industry, collaborations and acquisitions by key companies, and a robust trend of research and development expenditure in the life sciences market and academia are other reasons fuelling the market.
In 2022, North America has a dominating position in the cell dissociation market, and the region is also projected to be dominant in the future as well. This growth can be credited to the rising cases of glaucoma and cancer and the growing requirement for biopharmaceutical items.
In North America, the U.S. industry grips the dominating position, and it will advance at a CAGR of more than 17.2%, in the coming few years. This can be ascribed to the high emphasis on research and development associated with biotechnology.
Hence, the rising consciousness of stem cell research, the growing improvements in technology, and the rising requirement for modified drugs and monoclonal antibodies are the major factors contributing to the growth of the cell dissociation market.
